Physician profile
Kamaldeep Singh
NPI 1174755714
$4,942.13
in general payments reported to CMS, 2019-2025
21 companies · $717 in 2025
The $717 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $328 · 2021: $459 · 2022: $879 · 2023: $1,511 · 2024: $514 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,327.64 | 2019-2025 | Watchman, Avvigo Guidance System, Synergy |
| Abiomed | $795.65 | 2021-2025 | Impella |
| Medtronic, INC. | $393.33 | 2021-2025 | Symplicity G3, Corevalve Evolut R |
| Abbott Laboratories | $385.17 | 2021-2024 | Optis, Dragonfly Opstar, Coroflow |
| Shockwave Medical, INC | $278.34 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.18 | 2019-2025 | Lifevest |
| Edwards Lifesciences Corporation | $122.97 | 2022 | |
| Cvrx, INC. | $94.42 | 2023 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $89.52 | 2022 | |
| Teleflex LLC | $88.67 | 2025 | Orsiro Mission |
| Preventice Services, LLC | $45.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $36.60 | 2019 | |
| Amgen INC. | $33.70 | 2019 | |
| Irhythm Technologies, INC. | $26.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.74 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $16.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.34 | 2019 | |
| Pfizer INC. | $14.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.67 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.61 | 2019 | |
| Cardiovascular Systems INC. | $6.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamaldeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.